What is BNTX's market cap?

BioNTech SE (BNTX) is a listed stock with a live quote. The latest market cap on this page is $22.8B.

Where is BioNTech SE headquartered?

BioNTech SE is headquartered in Mainz.

How do I get BNTX news from the API?

Call GET /v1/news?tickers=BNTX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does BNTX news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for BNTX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the BNTX price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email sales@marketnewsapi.com.

BNTX · NASDAQ

BioNTech SE

$90.62 -0.02 (-0.02%)

Company overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates including BNT111, which is in a Phase II clinical trial for advanced melanoma; BNT112 in a Phase I/IIa clinical trial for prostate cancer; BNT113 in a Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 in a Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I clinical trial for ovarian cancer; and BNT116, a preclinical-stage product for non-small cell lung cancer.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $22.8B
Employees: 6,772
Headquarters: Mainz
Website: biontech.de
CEO: Ugur Sahin
Listed: October 10, 2019
P/E: -17.80
Dividend yield: 1.33%

Company financials

Revenue: $2.8B
Gross profit: $2B
Operating income: -$1.5B
EBITDA: -$815M
Net income: -$1.3B
EPS: -$5.09
Total assets: $21.1B
Total debt: $303M
Gross margin: 73.17%
Net margin: -44.95%
Earnings yield: -5.62%

Revenue segmentation

By product (FY 2025)

By region (FY 2025)

Showing FY 2025

Price chart

BNTX 1D NASDAQ O89.24H91.46L88.25C90.64+3.72 (+4.28%)Vol1.21M

News

Ticker	Type	Headline	Source	Published
BNTXBioNTech SE	Stock news	BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)	Seeking Alpha	Nov 4, 9:30:19 AM ET
BNTXBioNTech SE	Press release	Penn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment	Business Wire	Nov 4, 9:14:00 AM ET
BNTXBioNTech SE	Stock news	BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript	Seeking Alpha	Nov 3, 4:16:06 PM ET
BNTXBioNTech SE	Stock news	BioNTech Q3 Earnings Call Highlights	MarketBeat	Nov 3, 1:17:18 PM ET
BNTXBioNTech SE	Press release	BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update	GlobeNewswire	Nov 3, 6:45:05 AM ET
BNTXBioNTech SE	Stock news	The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings	24/7 Wall Street	Oct 27, 9:28:55 AM ET
BNTXBioNTech SE	Stock news	Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next	Investopedia	Oct 26, 4:01:44 PM ET
BNTXBioNTech SE	Stock news	Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady	24/7 Wall Street	Oct 26, 9:14:02 AM ET
BNTXBioNTech SE	Press release	A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets	GlobeNewswire	Oct 26, 8:53:00 AM ET
BNTXBioNTech SE	Press release	BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer	GlobeNewswire	Oct 26, 5:00:00 AM ET
BNTXBioNTech SE	Press release	BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy	GlobeNewswire	Oct 25, 3:30:00 AM ET
BNTXBioNTech SE	Stock news	Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports	The Motley Fool	Oct 22, 4:45:59 PM ET
BNTXBioNTech SE	Stock news	Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher	24/7 Wall Street	Oct 22, 1:55:24 PM ET
BNTXBioNTech SE	Stock news	BioNTech, Gilead to test drug combination in advanced breast cancer trial	Reuters	Oct 22, 7:24:06 AM ET
BNTXBioNTech SE	Press release	BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer	GlobeNewswire	Oct 22, 6:45:00 AM ET
BNTXBioNTech SE	Press release	BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026	GlobeNewswire	Oct 20, 6:45:00 AM ET
BNTXBioNTech SE	Press release	BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026	GlobeNewswire	Oct 19, 6:45:00 AM ET
BNTXBioNTech SE	Stock news	Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?	The Motley Fool	Oct 18, 2:32:00 PM ET
BNTXBioNTech SE	Stock news	Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline	The Motley Fool	Oct 17, 12:23:00 PM ET
BNTXBioNTech SE	Stock news	Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)	Defense World	Oct 17, 3:48:58 AM ET

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.